News

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Offers must pair strong compensation with operational and cultural support to succeed.

Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting.

Explore top dermatology conferences and meetings in April 2026 and let us know which ones you'll be attending!

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

Christopher Bunick, MD, PhD, and Almirall's Johnny Im discuss new data showing that tirbanibulin 1% ointment provides consistent efficacy, while expanded coverage is poised to improve patient access in the US.

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

Dermatology Times is looking back on the top stories in dermatology from the month of March.

The trial’s results may support earlier use of dual IL-17A/F inhibitors in patients with both skin and joint disease.

Experts discuss how clinicians translate clinical trial results into practical treatment decisions for alopecia areata.

At AAD 2026, Andrew Blauvelt, MD, presented robust PASI responses and favorable safety from ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation TYK2 inhibitor.

Learn more about the in-depth topics covered in the March 2026 print issue of Dermatology Times.

Dermatology Times is recapping our exclusive expert interviews from the month of March.

With so many new options in dermatology, personalized medicine may be replacing guideline-driven care.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of March

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Catch up on coverage from the fourth day of the 2026 American Academy of Dermatology Annual Meeting held in Denver, Colorado.

Posters from Allergan Aesthetics highlight the efficacy of investigational trenibotulinumtoxinE, along with new aesthetic trends in GLP-1 users.

The small protein therapeutic gave hidradenitis suppurativa patients greater reductions in inflammatory lesion counts after 32 weeks.

Jeff Yu, MD, discusses important issues in screening and addressing pediatric contact dermatitis at the AAD Annual Meeting.

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.